CKS1B is a 79-amino-acid protein encoded by the CKS1B gene (OMIM: 116900), essential for cyclin-dependent kinase (CDK) activity . It binds to CDK catalytic subunits (e.g., CDK1, CDK2) and regulates cell cycle progression by:
Facilitating ubiquitination of CDK inhibitors (e.g., p27) via SCF complexes .
Modulating CDK1 expression at the mRNA level, critical for mitotic entry .
Influencing proteasomal degradation of substrates like p130/Rb2 and securin .
CKS1 antibodies are widely used in cancer biology and cell cycle studies. Key applications include:
Detects CKS1 in lysates from breast cancer (MCF-7, T47D), hepatocellular carcinoma (Huh7), and leukemia (AML) cell lines .
Example: Anti-CKS1 antibody (ab72639) identifies a band at <19 kDa in Jurkat and HeLa cells .
Highlights nuclear CKS1 overexpression in oral squamous cell carcinoma (OSCC) and hepatocellular carcinoma (HCC) .
| Tissue/Cell Type | CKS1 Protein Level | CKS1 mRNA Level | Source |
|---|---|---|---|
| Normal oral mucosa | Undetectable | Low | |
| OSCC (Stage IV) | High (71% cases) | Moderate | |
| Breast cancer (MCF-7) | High | High | |
| Primary HMECs | Undetectable | Moderate |
Overexpression of CKS1 is linked to aggressive breast tumors (HR+ subtype), OSCC, and HCC .
In breast cancer, CKS1 depletion reduces Skp2 levels, elevates p27, and blocks G-M transition .
Inhibition of CKS1 in acute myeloid leukemia (AML) increases ROS accumulation, selectively inducing leukemic stem cell apoptosis while sparing healthy cells .
Preclinical studies show CKS1 siRNA reduces tumor growth in xenograft models .
p27-Independent Roles: CKS1 regulates S-phase entry via CDK2 activation, independent of Skp2-mediated p27 degradation .
Proteasomal Regulation: CKS1 turnover is post-translationally controlled in cancer cells, with protein levels exceeding mRNA expression .
Species Variability: Cks1 is dispensable in normal mammary epithelial cells but essential in cancer cells, suggesting tumor-specific dependency .